eprintid: 19487
rev_number: 14
eprint_status: archive
userid: 1589
dir: disk0/00/01/94/87
datestamp: 2016-01-19 10:01:45
lastmod: 2024-04-09 22:15:16
status_changed: 2016-01-19 10:01:45
type: article
metadata_visibility: show
creators_name: Widschwendter, Peter
creators_name: Friedl, Thomas WP
creators_name: Schwentner, Lukas
creators_name: DeGregorio, Nikolaus
creators_name: Jäger, Bernadette
creators_name: Schramm, Amelie
creators_name: Bekes, Inga
creators_name: Deniz, Miriam
creators_name: Lato, Krisztian
creators_name: Weissenbacher, Tobias
creators_name: Kost, Bernd
creators_name: Andergassen, Ulrich
creators_name: Jückstock, Julia
creators_name: Neugebauer, Julia
creators_name: Trapp, Elisabeth
creators_name: Fasching, Peter A.
creators_name: Beckmann, Matthias W.
creators_name: Schneeweiß, Andreas
creators_name: Schrader, Ines
creators_name: Rack, Brigitte
creators_name: Janni, Wolfgang
creators_name: Scholz, Christoph
title: The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
subjects: ddc-610
divisions: i-910400
abstract: Introduction: Obese breast cancer patients have worse prognosis than normal weight patients, but the level at which obesity is prognostically unfavorable is unclear.   Methods: This retrospective analysis was performed using data from the SUCCESS A trial, in which 3754 patients with high-risk early breast cancer were randomized to anthracycline- and taxane-based chemotherapy with or without gemcitabine. Patients were classified as underweight/normal weight (body mass index (BMI) < 25.0), overweight (BMI 25.0–29.9), slightly obese (BMI 30.0–34.9), moderately obese (BMI 35.0–39.9) and severely obese (BMI ≥ 40.0), and the effect of BMI on disease-free survival (DFS) and overall survival (OS) was evaluated (median follow-up 65 months). In addition, subgroup analyses were conducted to assess the effect of BMI in luminal A-like, luminal B-like, HER2 (human epidermal growth factor 2)-positive and triple-negative tumors.   Results: Multivariate analyses revealed an independent prognostic effect of BMI on DFS (p = 0.001) and OS (p = 0.005). Compared with underweight/normal weight patients, severely obese patients had worse DFS (hazard ratio (HR) 2.70, 95 % confidence interval (CI) 1.71–4.28, p < 0.001) and OS (HR 2.79, 95 % CI 1.63–4.77, p < 0.001), while moderately obese, slightly obese and overweight patients did not differ from underweight/normal weight patients with regard to DFS or OS. Subgroup analyses showed a similar significant effect of BMI on DFS and OS in patients with triple-negative breast cancer (TNBC), but not in patients with other tumor subtypes.   Conclusions: Severe obesity (BMI ≥ 40) significantly worsens prognosis in early breast cancer patients, particularly for triple-negative tumors.   Trial registration: Clinicaltrials.gov NCT02181101. Registered September 2005 
date: 2015
publisher: BioMed Central
id_scheme: DOI
ppn_swb: 1656105306
own_urn: urn:nbn:de:bsz:16-heidok-194871
language: eng
bibsort: WIDSCHWENDTHEINFLUEN2015
full_text_status: public
publication: Breast Cancer Research
volume: 17
number: 129
place_of_pub: London
pagerange: 1-11
issn: 1465-542X
citation:   Widschwendter, Peter ; Friedl, Thomas WP ; Schwentner, Lukas ; DeGregorio, Nikolaus ; Jäger, Bernadette ; Schramm, Amelie ; Bekes, Inga ; Deniz, Miriam ; Lato, Krisztian ; Weissenbacher, Tobias ; Kost, Bernd ; Andergassen, Ulrich ; Jückstock, Julia ; Neugebauer, Julia ; Trapp, Elisabeth ; Fasching, Peter A. ; Beckmann, Matthias W. ; Schneeweiß, Andreas ; Schrader, Ines ; Rack, Brigitte ; Janni, Wolfgang ; Scholz, Christoph  (2015) The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.  Breast Cancer Research, 17 (129).  pp. 1-11.  ISSN 1465-542X     
document_url: https://archiv.ub.uni-heidelberg.de/volltextserver/19487/1/13058_2015_Article_639.pdf